Thermo Fisher Scientific (NYSE:TMO) Upgraded by Piper Sandler to Hold Rating

Piper Sandler upgraded shares of Thermo Fisher Scientific (NYSE:TMO) to a hold rating in a research note released on Thursday morning,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. DZ Bank initiated coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 target price for the company. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price for the company. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $608.95.

Thermo Fisher Scientific Trading Down 1.4%

Shares of TMO stock opened at $475.12 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The business has a 50-day moving average price of $479.68 and a two-hundred day moving average price of $528.09. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $643.99. The firm has a market cap of $176.56 billion, a P/E ratio of 26.12, a price-to-earnings-growth ratio of 2.13 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same quarter in the previous year, the company posted $5.15 earnings per share. The company’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts anticipate that Thermo Fisher Scientific will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Insider Transactions at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Assetmark Inc. grew its holdings in shares of Thermo Fisher Scientific by 22.9% during the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after acquiring an additional 7,023 shares during the period. Mackenzie Financial Corp grew its holdings in shares of Thermo Fisher Scientific by 29.4% during the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after acquiring an additional 62,790 shares during the period. NEOS Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 28.6% during the 3rd quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock worth $24,913,000 after acquiring an additional 11,415 shares during the period. Factory Mutual Insurance Co. grew its holdings in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company’s stock worth $47,985,000 after acquiring an additional 2,500 shares during the period. Finally, North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $7,505,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.